Quantcast

Industry news that matters to you.  Learn more

Neogenix Oncology to Present Data on the Detection of Colorectal and Pancreatic Cancer at ASCO’s 2010 Annual Meeting on Molecular Makers in Cancer

Neogenix Oncology, Inc. announced today that it will present data from its new serum biomarker ELISA utilizing its NPC-1C antibody for patients with colorectal and pancreatic cancers. Results from the study will be presented at the American Society of Clinical Oncology (ASCO)-NCI-EORTC Annual Meeting on Molecular Makers in Cancer, to be held in Hollywood, Florida from October 18-20, 2010.

Revalesio Partners with Predictive Biomarker Sciences to Assess Potential Cancer Treatment

Revalesio Corporation announced today that it has contracted with Predictive Biomarker Sciences (PBS-Bio) to conduct studies related to the use of Revalesio’s novel anti-inflammatory therapeutic in treating cancer.

To jump-start drug development, PBS-Bio’s analysis helps pharmaceutical companies better understand how their drugs work and identifies biomarkers that can help predict which patients will respond to treatment.

Lilly to Close Singapore Discovery Center

Eli Lilly will be closing the Lilly Singapore Centre for Drug Discovery by the end of the year, according to an email sent out this morning by Jonathon Sedgwick, Managing Director & Chief Scientific Officer, Lilly Singapore Centre for Drug Discovery (LSCDD).

Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute Establish Powerful Alliance in Oncology

Sanofi-aventis and the Belfer Institute of Applied Cancer Science at the Dana-Farber Cancer Institute (DFCI) in Boston, Massachusetts, announced today that they have entered into a collaboration and licensce agreement to identify novel oncology targets for the development of new therapeutic agents directed at such targets and related biomarkers.

Aushon BioSystems Forms Scientific Advisory Board

Aushon BioSystems, Inc., a leading provider of advanced microarray products and laboratory services for biomarker discovery, development and analysis, announced today the formation of a Scientific Advisory Board consisting of internationally renowned physicians and scientists at the forefront of applying biomarker technology in clinical drug development.